These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Maternal-fetal outcomes of lamivudine treatment administered during late pregnancy to highly viremic mothers with HBeAg+ chronic hepatitis B]. Jiang HX, Han GR, Wang CM, Ji Y. Zhonghua Gan Zang Bing Za Zhi; 2012 Dec; 20(12):888-91. PubMed ID: 23522247 [Abstract] [Full Text] [Related]
10. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. Celen MK, Mert D, Ay M, Dal T, Kaya S, Yildirim N, Gulsun S, Barcin T, Kalkanli S, Dal MS, Ayaz C. World J Gastroenterol; 2013 Dec 28; 19(48):9377-82. PubMed ID: 24409065 [Abstract] [Full Text] [Related]
11. Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission. Sun W, Zhao S, Ma L, Hao A, Zhao B, Zhou L, Li F, Song M. BMC Gastroenterol; 2017 Apr 13; 17(1):51. PubMed ID: 28407735 [Abstract] [Full Text] [Related]
12. Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus. Yu MM, Jiang Q, Ji Y, Wu KH, Ju LL, Tang X, Yang YF. J Clin Virol; 2014 Sep 13; 61(1):55-60. PubMed ID: 24994007 [Abstract] [Full Text] [Related]
13. Safety and efficacy of telbivudine in late pregnancy to prevent mother-to-child transmission of hepatitis B virus: A multicenter prospective cohort study. Hu Y, Xu C, Xu B, Hu L, Liu Q, Chen J, Liu J, Liu L, Yang J, Chen T, Wen J, Jiang N, Zhang Y, Cao M, Feng J, Lin X, Wang Z, Xu B, Zhou YH. J Viral Hepat; 2018 Apr 13; 25(4):429-437. PubMed ID: 29193547 [Abstract] [Full Text] [Related]
14. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Hepatology; 2014 Aug 13; 60(2):468-76. PubMed ID: 25187919 [Abstract] [Full Text] [Related]
15. [Telbivudine for prevention of perinatal transmission in pregnant women infected with hepatitis B virus in immune-tolerant phase: a study of efficacy and safety of drug withdrawal]. Sheng QJ, Ding Y, Li BJ, Bai H, Zhang C, Han C, Fan YX, Li YW, Dou XG. Zhonghua Gan Zang Bing Za Zhi; 2016 Apr 13; 24(4):258-64. PubMed ID: 27470623 [Abstract] [Full Text] [Related]
16. [The safety of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women after discontinuation]. Deng Y, Wu W, Zhang D, Hu P, Kang J, Yang Y, Zeng W. Zhonghua Gan Zang Bing Za Zhi; 2015 Aug 13; 23(8):586-9. PubMed ID: 26447621 [Abstract] [Full Text] [Related]
17. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. Zheng MH, Shi KQ, Dai ZJ, Ye C, Chen YP. Clin Ther; 2010 Apr 13; 32(4):649-58. PubMed ID: 20435234 [Abstract] [Full Text] [Related]
19. Efficacy and safety of telbivudine treatment: an open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection. Han GR, Jiang HX, Yue X, Ding Y, Wang CM, Wang GJ, Yang YF. J Viral Hepat; 2015 Sep 13; 22(9):754-62. PubMed ID: 25641421 [Abstract] [Full Text] [Related]